Determination of fexofenadine in human plasma using 96-well solid phase extraction and HPLC with tandem mass spectrometric detection
- 29 June 2004
- journal article
- Published by Elsevier BV in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 35 (4), 837-846
- https://doi.org/10.1016/j.jpba.2004.02.016
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- MDR1 gene polymorphisms and disposition of the P‐glycoprotein substrate fexofenadineBritish Journal of Clinical Pharmacology, 2002
- Determination of fexofenadine in human plasma and urine by liquid chromatography–mass spectrometryJournal of Chromatography B, 2002
- Identification of functionally variant MDR1 alleles among European Americans and African AmericansClinical Pharmacology & Therapeutics, 2001
- P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugsInt. Journal of Clinical Pharmacology and Therapeutics, 2000
- FexofenadineDrugs, 2000
- Inhibition of P-Glycoprotein–Mediated Drug TransportCirculation, 1999
- Clinical Pharmacology of New Histamiine H1 Receptor AntagonistsClinical Pharmacokinetics, 1999
- A Sensitive HPLC Method for the Determination of Terfenadine and Its Metabolite in Human PlasmaJournal of Liquid Chromatography, 1994
- Determination of terfenadine and terfenadine acid metabolite in plasma using solid-phase extraction and high-performance liquid chromatography with fluorescence detectionJournal of Chromatography B: Biomedical Sciences and Applications, 1991